Velez, Maria A. http://orcid.org/0000-0001-5197-4719
Glenn, Beth A.
Garcia-Jimenez, Maria
Cummings, Amy L. http://orcid.org/0000-0003-0472-392X
Lisberg, Aaron
NaƱez, Andrea
Radwan, Yazeed
Lind-Lebuffe, Jackson P.
Brodrick, Paige M.
Li, Debory Y.
Fernandez-Turizo, Maria J.
Gower, Arjan
Lindenbaum, Maggie
Hegde, Manavi
Brook, Jenny
Grogan, Tristan
Elashoff, David
Teitell, Michael A. http://orcid.org/0000-0002-4495-8750
Garon, Edward B. http://orcid.org/0000-0001-7077-8801
Article History
Received: 14 December 2022
Accepted: 28 June 2023
First Online: 2 August 2023
Competing interests
: E.B.G. has been a consultant and/or advisor for Abbvie; ABL-Bio; AstraZeneca, Boehringer-Ingelheim; Bristol-Myers Squibb; Dracen Pharmaceuticals; EMD Serono; Eisai; Eli Lilly; Gilead; GlaxoSmithKline; Ipsen; Merck; Natera; Novartis; Personalis; Regeneron; Sanofi; Shionogi; and Xilio. E.B.G. has received grant or research support from ABL-Bio; AstraZeneca; Bristol-Myers Squibb; Dynavax Technologies; Eli Lilly; EMD Serono; Genentech; Iovance Biotherapeutics; Merck; Mirati Therapeutics; Neon; and Novartis. A.L. has received commercial research grants from Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL, eFFECTOR Therapeutics. A.E.L. has served as a consultant or on the advisory board for, AstraZeneca, Bristol-Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, MorphoSys, Eli Lilly, Oncocyte, Novartis, Regeneron, Janssen oncology, Sanofi group of companies. M.A.V., B.A.G., M.G.-J., A.N., Y.R., J.P.L.-L., P.M.B., D.Y.L., M.J.F.-T., A.G., M.L., M.H., J.B. and T.G. declare no competing interests.